Kornimate/medical-research-clean huggingface dataset:
loewenkids - infections and the development of the immune system

Conditions: Infectious Diseases

Summary: the purpose of this study is to determine in what way infections, microbiome, and vaccinations during childhood interact in shaping the development of immunity and tolerance. the investigators collect and use data from a birth cohort focusing on infectious diseases during childhood and apply a life course perspective.

the goal of the study is to capture the complete history of exposure towards microbial challenges in the first six years of life and to study interactions between different components of microbial exposure as well as effects on the development of immunity. the investigators apply a diary in which parents document symptoms of respiratory and gastrointestinal infections of their child, and collect nasal swabs and stool samples obtained on first day of symptoms. in addition, the investigators collect nasal swabs and stool samples once per year during an asymptomatic period. the investigators intend to collect venous blood from children participating in the study at the age of six years. in a subsample (called intensive subcohort), the investigators collect asymptomatic probes three monthly during the first two years of life and obtain venous blood of the children at the age of one and two years. the study sample is 782 participants, with 285 participants in the intensive subcohort. symptomatic samples will be analyzed by means of multiplex polymerase chain reaction (pcr). in addition, the investigators will assess microbial compositions based on next generation sequencing and apply multiplex panels to study parameters of unspecific humoral immune response. the study will allow to assess homologous and heterologous effects of infections and vaccinations measuring specific humoral immune response. in collaboration with immunologists, immune phenotypes will be studied and functional tests will be conducted. the investigators will use allergic dermatitis at the age of two as a primary proxy outcome and target asthma at the age of six years as a definitive clinical endpoint.

Eligibility criteria:
inclusion criteria: * newborn in a study region exclusion criteria: * parents \< 18 years old * insufficient knowledge of the german language (parents)

Keywords: birth cohort infectious diseases microbiome immune system immune response
assessment of post-traumatic stress disorder (ptsd) in patients monitored for cytomegalovirus (cmv) seroconversion during pregnancy,

Conditions: Mothers; Cytomegalovirus Infections; Pregnancy Related

Summary: reports of maternal seroconversion to cmv during pregnancy can be extremely stressful. this virus is little known to the general public and searching for information on the internet quickly leads to a consultation of a site mentioning the risk of severe psychomotor retardation in the event of prenatal cytomegalovirus infection. the psychological repercussions in the event of prenatal cmv infection with criteria of severity, leading or not to a request for img, is undeniable, but no study has investigated the consequences of seroconversion to cmv without transmission of the virus to the patient fetus, or in the case of transmission without criteria of seriousness, on the patient's experience during and after her pregnancy. such a study would, if necessary, improve the care and support of these future mothers


Eligibility criteria:
inclusion criteria: * adults * referred to the 3 dan centers with maternal seroconversion to cmv during their pregnancy, confirmed, with or without confirmed prenatal transmission. * presence of ultrasound signs without criteria of seriousness if the materno-fetal infection is proven. * support between january 1, 2008 and december 31, 2020. * no opposition from patient exclusion criteria: * reversed or anteconceptional cmv seroconversion * concomitant infection with another infectious agent and suspected cross-reaction * multiple pregnancy * ultrasound and / or mri severity criteria * medical termination of pregnancy * fetal death in utero * birth \<32 weeks and / or birth weight \<1500 grams (birth criteria in maternity level iia) * intercurrent event that may be the cause of an abnormality in psychomotor development * patients protected by justice

Keywords: cmv pregnancy ptsd
swiss primary biliary cholangitis cohort study

Conditions: Liver Cirrhosis, Biliary

Summary: research project in which biological material is sampled and health-related medical data is collected. in addition, already existing health-related medical data are used for further research. coded data are used.

enrolment visit and one follow-up visit at least once a year are planned. whole blood is collected for biobanking once a year. optionally, if available and collected during normal clinical procedures, liver fragments are obtained. to collect high quality prospective data on a rare disease in order to elucidate epidemiology, natural history, response to treatment and outcome. in addition, the biobank allows addressing specific scientific issues on a variety of open questions. the cohort will provide a platform for carrying out scientific research projects on pbc. in addition, the cohort will allow collaboration with reference networks on pbc abroad.

Eligibility criteria:
inclusion criteria: * diagnose of primary biliary cholangitis (according to easl clinical practice guidelines: management of cholestatic liver diseases). * subjects with isolated anti-mitochondrial antibodies and/or isolated pbc-specific anti-nuclear antibodies are also included * patients/subjects aged at least 18 years and living in switzerland are included exclusion criteria: * n/a
laparoscopic sentinel node navigation surgery for gastric cancer

Conditions: Gastric Cancer

Summary: there are few reports on a dual dye and isotope approach using laparoscopy in gastric cancer sentinel node mapping. the aim of this study was to evaluate the feasibility of laparoscopic limited gastrectomy with sentinel basin(sb) dissection for gastric cancer using simultaneous indocyanine green (icg) and 99mtc-antimony sulfur colloid (asc) injections.

prospective phase ii clinical trials for sentinel node navigation surgery(snns) in early gastric cancer. laparoscopic snns: 1. icg and 99mtc-antimony sulfur colloid (asc) submucosal injection under intraoperative endoscopy 2. sentinel node basin identification and dissection 3. sentinel nodes picking in back table 4. frozen biopsy of sentinel nodes(hematoxylin and eosin staining and immunohistochemistry for cytokeratin) 5. if the sentinel node biopsy by frozen section is negative, limited gastrectomy will be performed or if positive, radical d2 gastrectomy will be performed. sample size: 100 cases study duration: 5 years( 2year enrollment, 3 year follow-up)

Eligibility criteria:
inclusion criteria: * age 20-80 * informed consent * no other malignancies * ct1n0 stage gastric cancers \< 4cm * no allergic history of isotope exclusion criteria: * patients eligible for endoscopic submucosal dissection(esd) with absolute indication

Keywords: gastric cancer sentinel node navigation surgery dual method recurrence
induction with foley or misoprostol (inform) study

Conditions: Pre-eclampsia; Fetus or Newborn; Effects of Induction of Labor

Summary: between 40,000 and 80,000 pregnant women die annually from pre-eclampsia and eclampsia. magnesium sulphate and anti-hypertensive therapies can reduce the morbidity associated with pre-eclampsia. the only cure, however, comes with delivery. prompt delivery of the baby, preferably by vaginal route, is vital in order to achieve good maternal and neonatal outcomes. induction of labour is therefore a critical intervention in order to prevent morbidity to both mother and baby. two low cost interventions - oral misoprostol tablets and transcervical foley catheterization - are already used by some in low resource settings, but their relative risks and benefits are not known. these interventions could optimize the care pathway for women needing induction of labour. this is especially important in low resource settings where improvement is most needed and the potential to reduce the maternal and neonatal mortality and morbidity is the greatest. the ideal induction agent would result in a relatively short induction to delivery interval without risk to fetus and with low rates of emergency caesarean section. the induction to delivery interval is especially important in pre-eclampsia and eclampsia where the condition may deteriorate rapidly until delivery. inductions with prostaglandins, including misoprostol, are sometimes associated with uterine hyperstimulation and consequent fetal hypoxia, whilst the effectiveness and safety of foley catheter as an induction agent has been persistently questioned. this study will identify the risk, benefits and trade-offs in efficacy, safety, acceptability and cost of these two low cost induction methods.

this is a pragmatic, open-label, randomised control trial of two methods for labour induction among women with pre-eclampsia. women requiring delivery for preeclampsia in two hospitals in nagpur, india will be randomised to one of two treatment groups: transcervical foley catheter or oral misoprostol tablets.

Eligibility criteria:
inclusion criteria: * ongoing pregnancies with a live fetus in whom the decision has been made to induce vaginal delivery because of preeclampsia or uncontrolled hypertension. women will be included irrespective of whether an intrapartum caesarean section on fetal grounds or would be considered or not. * women age ≥18 years * signed informed consent form exclusion criteria: * • women with previous caesarean sections * those unable to give informed consent * multiple pregnancy * history of allergy to misoprostol * ruptured membranes * chorioamnionitis (by clinical diagnosis)

Keywords: pre-eclampsia labor induction misoprostol foley catheter
early detection of lung cancer in a high-risk population defined by pft, biomarkers, and ct scanning

Conditions: Lung Cancer

Summary: lung cancer is the number one cancer killer in kentucky and has a very high incidence within the 5th congressional district of kentucky (110.8 cases per 100,000 in period 1996-2000). surgical removal provides the best chance for cure. unfortunately, the majority of lung cancer cases are detected in an advanced stage, when surgical resection is impossible. this leads to shorter survival rates and increased mortality rates for lung cancer, increased patient suffering, and greater cost to the healthcare system. methods that favor earlier detection are therefore crucial for successful treatment. one such method, low-dose spiral computed tomography (ct) is being studied to determine whether its use as a screening method will lead to earlier detection and earlier intervention, perhaps impacting survival and mortality in lung cancer. this method has a modest sensitivity to detect lung cancer, but low specificity, which leads to many false positives and a low negative predictive value. the present study is designed to address both of these limitations by: 1) identifying individuals in the population at highest risk for developing lung cancer (due to smoking habits and decreased pulmonary function) for subsequent ct screening, and 2) performing biomarker testing in conjunction with the ct scan to improve the ability to discern individuals with benign lung nodules from those with malignant tumors. the 5th congressional district of kentucky has one of the highest rates of lung cancer in the nation and is an ideal location to test the validity (sensitivity and specificity), feasibility (negative and positive predictive value), and efficacy (stage distribution shift to earlier stage disease, increased survival, and decreased cancer-specific mortality) of these strategies to enhance early detection.


Eligibility criteria:
inclusion criteria: * age 55-75 years old. * identification of a primary care physician (can be identified by study staff if needed). * fev1/fvc \<70% (gold 1 or higher copd) (poor breathing function). * \> or = 40 pack-year current or former (within the last 10 years) tobacco use (i.e. heavy cigarette smoking history). exclusion criteria: * enrolled in any other lung screening or lung cancer prevention trial. * chest ct within the prior 12 months. * inability to lie flat with arms raised above the head. * current or prior personal history of lung cancer. * prior history of cancer within the last five years or currently receiving treatment for cancer, except adequately treated non-melanomatous skin cancer or in-situ cervical cancer. * life expectancy of less than 5 years. * patients requiring supplemental oxygen. * inability to give informed consent.

Keywords: lung cancer screening
biobehavioral-cytokine interactions in ovarian cancer

Conditions: Ovarian Neoplasms

Summary: the purpose of this study is to understand relationships between behavioral factors, hormones, and chemicals produced by the body that may help tumor growth in ovarian cancer.

ovarian cancer is the second most common gynecologic cancer. because of low rates of survival for the majority of ovarian cancer patients, identification of factors contributing to tumor progression is of paramount importance. epidemiologic studies have suggested an association between biobehavioral factors such as life stress, depression, low social support and cancer progression. direct links have been demonstrated between biobehavioral factors and cytokines supporting angiogenesis, the formation of new blood vessels that enhance tumor growth and progression. however, little is known regarding tumor associated macrophages (tam) and interactions between tam tumor cells in a way that favors tumor growth, but there is preliminary data indicating that ovarian cancer patients with higher levels of depressive symptoms and life stress have greater tam production of matrix metalloproteinase-9, a key molecule promoting angiogenesis and tumor invasion. we also have preliminary data that ovarian cancer patients with high levels of depressive symptoms accompanied by low social support have greater tumor expression of a number of genes related to inflammation and tumor progression.

Eligibility criteria:
inclusion criteria: * patients with a histologic diagnosis of epithelial ovarian cancer, primary peritoneal carcinoma, or fallopian tube cancer; figo stage i to iv defined surgically at the completion of the initial abdominal surgery and with appropriate tissue available for histologic evaluation. * patients with the following histologic epithelial cell types are eligible: serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma, undifferentiated carcinoma, clear cell carcinoma, mixed epithelial carcinoma, or adenocarcinoma not otherwise specified. however, the histologic features must be compatible with primary mullerian epithelial adenocarcinoma. * gog performance status 0-3 exclusion criteria: * patients with a diagnosis of borderline epithelial ovarian tumor (formerly: tumors of low malignant potential" or recurrent invasive epithelial ovarian, primary peritoneal, or fallopian tube cancer treated with chemotherapy or radiotherapy previously are excluded. * patients who received neoadjuvant chemotherapy for ovarian, primary peritoneal, or fallopian tube carcinoma are excluded. * non-epithelial ovarian cancers or metastases to the ovaries from organs are excluded. * previous cancer diagnosis except for basal cell carcinoma of the skin or history of lymphoma. * pregnancy or age \<18 years old * use of systemic glucocorticoids such as prednisone or decadron in the last 30 days * comorbid conditions: addison's disease, autoimmune hepatitis, hepatitis b, hepatitis c, aids or hiv, lupus erythematosus, mixed connective tissue disease, rheumatoid arthritis. * inability to accurately answer questions (e.g. a condition such as dementia)

Keywords: ovarian neoplasms
efficacy and safety of everolimus in de novo kidney transplant recipients of ecd or aki donors

Conditions: Transplantation of Kidney; Expanded Criteria Donor; ECD

Summary: single center, open-label randomized-control trial population: de novo 48 kidney transplant recipients (age 18-75 years) from ecd/aki donors compare: everolimus with low dose cni and prednisolone versus standard immunosuppressive regimen objective: to evaluate efficacy of everolimus with low dose cni in de novo kidney transplant recipients of ecd/aki donors primary endpoint: mean egfr (ckd-epi) at 12 months post-transplantation

secondary endpoints: * to assess renal function by means of egfr (cockcrault and gault formula), at -month 6 and 12 post-transplantation * to assess incidence of the individual composite endpoints including bpar, graft loss and death at month 6 and 12 post-transplantation * to assess the incidence and duration of renal replacement therapy * to assess the incidence of chronic allograft nephropathy (if/ta) at month 12 * to assess renal function by means of serum creatinine at month 6 and 12 post-transplantation * to compare the overall safety and tolerability (incidence of aes and saes, infections, discontinuations due to aes, lab abnormalities, wound and surgical complications) at month 6 and 12 post-transplantation definition of ecd * brain-dead donor \> 60 years old or * donor age \> 50 years old with two of the following criteria; * history of ht * terminal scr. ≥ 1.5 mg/dl * death from cerebrovascular accident definition of aki donor * brain-dead donor with an increase of scr. ≥ 0.3 mg/dl from baseline

Eligibility criteria:
inclusion criteria: * age 18-75 years * recipients of first ddkt from ecd or aki donors * patient willing to participate in the study exclusion criteria: * multi-organ recipients * organ donation after cardiac death (dcd). * pra \> 20 % or with historical peak pra \> 50% * patients who lost first graft due to immunological reason within the first year post-transplantation. * abo incompatible transplants or positive cross-match * patients with chronic inflammatory bowel disease. * severe allergy requiring acute treatment, or any known hypersensitivity to everolimus, thymoglobulin * thrombocytopenia (platelet \< 75,000/mm3), anc \< 1,500 /mm3 or leucopenia (leucocytes \< 2,500/mm3), or hb \< 6 g/dl * chronic active hcv, hiv, or hbsag positive * history of malignancy during the last five years, except squamous or basal cell carcinoma of the skin. * ongoing infection requiring treatment with a systemic antibiotic. * patient with severe hypercholesterolemia (\> 300 mg/dl) or hypertriglyceridemia (\> 600 mg/dl) that cannot be controlled * evidence of severe liver disease. * severe restrictive or obstructive pulmonary disorders. * pregnant or nursing (lactating) women. * patient who refuse to participate into the study or would like to withdraw from the study.

Keywords: kidney transplantation ecd
does vitamin c reduce finger stiffness after distal radius fractures?

Conditions: Finger Stiffness; Distal Radius Fracture

Summary: the reported prevalence of disproportionate pain and disability among patients recovering from a fracture of the distal radius varies widely. literature reports numbers between 1% and 37%, perhaps in part because it is poorly defined, known by so many different names, subjective, and unverifiable. the investigators are interested in the effect of vitamin c after distal radius fractures on objective measurement of finger motion, patient reported outcome measures, and pain intensity, instead of the previously used, subjective and imprecise criteria for complex regional pain syndrome. patients presenting to the hand and orthopaedic trauma services of mgh with a distal radius fracture will be asked to participate in this clinical trial. patient will be randomly assigned to take either placebo or vitamin c 500 mg until full finger motion is attained as regarded by the treating physician at follow-up or for 6 weeks. the investigators hypothesize no difference in finger stiffness at 6 weeks measured by distance to palmar crease of the index through little finger between patients taking vitamin c or placebo after a distal radius fracture. additionally, the investigators assess finger stiffness by range of motion and stiffness of the thumb, and difference in promis upper extremity function and pain score both measured at six months.


Eligibility criteria:
inclusion criteria: * all adult (age 18 or greater) patients presenting to the hand and orthopaedic trauma services of the massachusetts general hospital (mgh) within two weeks of a fracture of the distal radius, either operatively or nonoperatively treated exclusion criteria: * patients with severe kidney failure, known allergy for vitamin c or pregnancy * multiple fractures, except for ulna fractures

Keywords: finger stiffness range of motion distal radius fracture vitamin c
frequency of hemorrhages associated with the functional anomalies of willebrand factor in emergency patients

Conditions: Von Willebrand Diseases

Summary: ecmo has improved the outcome of heart or respiratory failure and carcinogenic shock and are increasingly used. however bleeding complications occurring in up to 50% of patients are poorly understood and worsen the overall results. the aim is to investigate the occurence of bleeding and its frequency according to the type of ecmo either veno-arterial or veno-venous. the investigators also want to assess the relation of bleeding with von willebrand factor defects.


Eligibility criteria:
inclusion criteria: * informed consent of patient or person in charge * patient supplied by an ecmo for cardiac or respiratory failure and referred to lille university hospital * patient affiliated to "french social security" exclusion criteria: * pregnant woman * no consent * no affiliation to * patient affiliated to ' * preexisting bleeding disorders

Keywords: mechanical circulatory support bleeding, acquired von willebrand disease acquired von willebrand disease
impact of ticagrelor on the endothelial healing following drug-eluting stent implantation in the patients with acute coronary syndrome

Conditions: Acute Coronary Syndrome; Acute Myocardial Infarction; Unstable Angina (Intermediate Coronary Syndrome)

Summary: the investigators hypothesized that ticagrelor may enhance endothelial healing after des implantation by increasing adenosine concentrations by the inhibition of adenosine uptake into erythrocytes, compared to clopidogrel. thus, the investigators will evaluate the extent of endothelialization (stent strut coverage) and neointimal hyperplasia (neointimal thickness) 3 months after des implantation by optical coherence tomography (oct)


Eligibility criteria:
inclusion criteria: * patients ≥ 20 years old * patients who are hospitalized and expected to undergo pci for acute coronary syndrome, including acute myocardial infarction and unstable angina. exclusion criteria: * age \> 80 years * cardiogenic shock or unstable patients * increased risk of bleeding, anemia, thrombocytopenia * a need for oral anticoagulation therapy * pregnant women or women with potential childbearing * life expectancy \< 1 year

Keywords: ticagrelor strut coverage des acs oct